Live Breaking News & Updates on Chairman Krishna Ella
Stay updated with breaking news from Chairman krishna ella. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bharat Biotech, Serum Institute arm Bilthoven Biologicals to collaborate for oral polio vaccine thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Bharat Biotech, University of Sydney sign MoU for vaccine research thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Mar 04 2021, 10:41 PM March 03 2021, 5:13 PM March 04 2021, 10:41 PM (Bloomberg) An Indian coronavirus vaccine that generated controversy when it was granted emergency approval before finishing its final stage testing has shown to provide strong protection against Covid-19 in an interim analysis of an advanced clinical trial. (Bloomberg) An Indian coronavirus vaccine that generated controversy when it was granted emergency approval before finishing its final stage testing has shown to provide strong protection against Covid-19 in an interim analysis of an advanced clinical trial. Covaxin, which was co-developed by Hyderabad-based Bharat Biotech International Ltd. and the Indian Council of Medical Research, showed an efficacy rate of 81% in those without prior infection after a second dose, the company said in a statement Wednesday. Thatâs better than Bharat Biotechâs guidance last year of around 60% and the countryâs benchmark of 50% for vacc ....
People criticised us but I feel proud today : Bharat Biotech chairman speaks on Covaxin s journey Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus BusinessToday.In | March 4, 2021 | Updated 14:13 IST Bharat Biotech Chairman Krishna Ella After Bharat Biotech s Covaxin showed 81 per cent efficacy in the phase three trial results, the company s Chairman Krishna Ella took a dig at those who had earlier questioned the credibility of the vaccine. In a video message, Ella said: Remembering people criticising us saying our data is not transparent, not in the public domain, I am today proud to say that our data are in the public domain in six publications. If people have got patience, they should read those articles . ....
Delays Over Pricing Hold Back India s Vital Vaccine Rollout Delays Over Pricing Hold Back India s Vital Vaccine Rollout On Sunday, Serum s billionaire Chief Executive Officer Adar Poonawalla said Indian officials have orally agreed to buy 100 million doses at a special price of 200 rupees a shot, below the about $4 to $5 price tag given to the U.K. government. A health worker opens a deep freezer during a Covid-19 vaccine dry run in Delhi, Jan. 2. Highlights Officials have orally agreed to buy 100 million doses at Rs 200: Serum Over 10 million people have been affected by the virus in India As major countries like the U.S. and China race to vaccinate their populations with rapidly approved shots, tens of millions of doses prepared for India are sitting in storage despite having been authorized for use. ....